Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.61 |
| ▸ | TPH1 | P17752 | 14/20 | 0.53 |
| ▸ | TPH2 | Q8IWU9 | 5/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869837 | 1.00 | GRIA2 (0.61) | GRIA2TPH1TPH2SLC7A5 | |
| SCHEMBL12159891 | 0.90 | TPH1 (0.62) | TPH1TPH2SLC7A5 | |
| SCHEMBL872205 | 0.84 | TPH1 (0.52) | TPH1TPH2 | |
| SCHEMBL872206 | 0.84 | TPH1 (0.52) | TPH1TPH2 | |
| SCHEMBL20274827 | 0.84 | TPH1 (0.55) | TPH1TPH2SLC7A5 | |
| SCHEMBL25356410 | 0.83 | GRIA2 (0.81) | GRIA2TPH1SLC7A5 | |
| SCHEMBL31688735 | 0.83 | GRIA2 (0.81) | GRIA2TPH1SLC7A5 | |
| SCHEMBL25356408 | 0.83 | GRIA2 (0.81) | GRIA2TPH1SLC7A5 | |
| SCHEMBL20274810 | 0.82 | TPH1 (0.59) | TPH1TPH2SLC7A5 | |
| SCHEMBL869893 | 0.82 | TPH1 (0.61) | TPH1TPH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TERSERA THERAPEUTICS LLC | 2009-02-26 | — | — | US | claimed |
| CN-101351451-A | Polycyclic amino acid derivatives and methods of use thereof | LEXICON GENETICS INC (US) | 2009-01-21 | — | — | CN | claimed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | claimed |
| EP-2386547-B1 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2014082034-A1 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME | LEXICON PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20130303763-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NECROTIZING ENTEROCOLITIS | LEXICON PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| WO-2013148978-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NECROTIZING ENTEROCOLITIS | LEXICON PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| CN-101351451-B | Polycyclic amino acid derivatives and methods of use thereof | LEXICON PHARMACEUTICALS INC | 2013-02-20 | — | — | CN | disclosed |
| EP-2504008-A1 | METHODS AND ASSAYS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Lexicon Pharmaceuticals, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| CN-102711757-A | Methods and assays for treating irritable bowel syndrome | LEXICON PHARMACEUTICALS INC | 2012-10-03 | — | — | CN | disclosed |
| EP-1984344-B1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2386547-A1 | Multicyclic amino acid derivatives and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-8039086-B2 | Bonding material, process for producing the same, and honeycomb structure made with the same | NGK INSULATORS, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20110124667-A1 | METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | LEXICON PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| WO-2011063181-A1 | METHODS AND ASSAYS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | LEXICON PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| CN-101969952-A | Compositions comprising tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS INC | 2011-02-09 | — | — | CN | disclosed |
| CN-101815534-A | methods and compositions for treating pulmonary hypertension and related diseases and disorders | LEXICON PHARMACEUTICALS INC | 2010-08-25 | — | — | CN | disclosed |
| CN-101801385-A | Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein | LEXICON PHARMACEUTICALS INC | 2010-08-11 | — | — | CN | disclosed |
| CN-101784269-A | methods of treating serotonin-mediated diseases and disorders | LEXICON PHARMACEUTICALS INC | 2010-07-21 | — | — | CN | disclosed |
| CN-101351451-A | Polycyclic amino acid derivatives and methods of use thereof | LEXICON GENETICS INC (US) | 2009-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TPH1, PAH, TPH2 | GRIA2 2012/4885TPH1 1/4885TPH2 3/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | GRIA2 291/4885TPH1 3/4885TPH2 4/4885 |
| US-20110124667-A1 | METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, HNMT, SLC10A2 | GRIA2 1496/4885TPH1 85/4885TPH2 63/4885 |
| US-20130303763-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NECROTIZING ENTEROCOLITIS | TPH1, TPH2, VIP | GRIA2 3749/4885TPH1 1/4885TPH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.